{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:22Z","timestamp":1793413882443,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02994-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:45:32Z","timestamp":1784702732000},"page":"3555-3563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins"],"prefix":"10.1007","volume":"49","author":[{"given":"Alice","family":"Del Zoppo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Moriconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Rebelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tric\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-8253","authenticated-orcid":false,"given":"Anna","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2994_CR1","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1111\/dom.16471","volume":"27","author":"L Lin","year":"2025","unstructured":"Lin L, Chen P, Zhang Y et al (2025) Burden of type 2 diabetes mellitus and risk factor attribution among older adults: A global, regional, and national analysis from 1990 to 2021, with projections up to 2040. Diabetes Obes Metab 27:4330\u20134343. https:\/\/doi.org\/10.1111\/dom.16471","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2994_CR2","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.2337\/dc26-S013","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2025) Older Adults: Standards of Care in Diabetes-2026. Diabetes Care 49(1):S277\u2013S296. https:\/\/doi.org\/10.2337\/dc26-S013","journal-title":"Diabetes Care"},{"key":"2994_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2024.12.006","volume":"282","author":"AJ Nelson","year":"2025","unstructured":"Nelson AJ, Kaltenbach LA, McGuire DK et al (2025) Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics. Am Heart J 282:51\u201357. https:\/\/doi.org\/10.1016\/j.ahj.2024.12.006","journal-title":"Am Heart J"},{"key":"2994_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-024-02154-w","volume":"23","author":"MU Ali","year":"2024","unstructured":"Ali MU, Mancini GBJ, Fitzpatrick-Lewis D et al (2024) The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis. Cardiovasc Diabetol 23:72. https:\/\/doi.org\/10.1186\/s12933-024-02154-w","journal-title":"Cardiovasc Diabetol"},{"key":"2994_CR5","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L et al (2024) Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation 150:1781\u20131790. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071689","journal-title":"Circulation"},{"key":"2994_CR6","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41598-025-86172-y","volume":"15","author":"S Hunsuwan","year":"2025","unstructured":"Hunsuwan S, Boongird S, Ingsathit A et al (2025) Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease. Sci Rep 15:1667. https:\/\/doi.org\/10.1038\/s41598-025-86172-y","journal-title":"Sci Rep"},{"key":"2994_CR7","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2337\/dc22-0772","volume":"46","author":"JM Rodriguez-Valadez","year":"2023","unstructured":"Rodriguez-Valadez JM, Tahsin M, Fleischmann KE et al (2023) Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression. Diabetes Care 46:1300\u20131310. https:\/\/doi.org\/10.2337\/dc22-0772","journal-title":"Diabetes Care"},{"key":"2994_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s41999-025-01168-1","volume":"16","author":"V Boccardi","year":"2025","unstructured":"Boccardi V, Bahat G, Balci C et al (2025) Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes. Eur Geriatr Med 16:1231\u20131247. https:\/\/doi.org\/10.1007\/s41999-025-01168-1","journal-title":"Eur Geriatr Med"},{"key":"2994_CR9","doi-asserted-by":"publisher","first-page":"100617","DOI":"10.1016\/j.lanepe.2023.100617","volume":"29","author":"ME Malik","year":"2023","unstructured":"Malik ME, Falkentoft AC, Jensen J et al (2023) Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur 29:100617. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100617","journal-title":"Lancet Reg Health Eur"},{"key":"2994_CR10","doi-asserted-by":"publisher","first-page":"109035","DOI":"10.1016\/j.diabres.2021.109035","volume":"180","author":"F Rea","year":"2021","unstructured":"Rea F, Ciardullo S, Savar\u00e9 L, Perseghin G, Corrao G (2021) Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. Diabetes Res Clin Pract 180:109035. https:\/\/doi.org\/10.1016\/j.diabres.2021.109035","journal-title":"Diabetes Res Clin Pract"},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385:1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"key":"2994_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"10","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 10:653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2994_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ph19010009","volume":"19","author":"IS Alhomoud","year":"2025","unstructured":"Alhomoud IS, Alamer KA (2025) Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease. Pharmaceuticals (Basel) 19:9. https:\/\/doi.org\/10.3390\/ph19010009","journal-title":"Pharmaceuticals (Basel)"},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD et al (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care 43:468\u2013475. https:\/\/doi.org\/10.2337\/dc19-1476","journal-title":"Diabetes Care"},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/M18-1569","volume":"170","author":"MP Gilbert","year":"2019","unstructured":"Gilbert MP, Bain SC, Franek E, LEADER Publication Committee on behalf of the LEADER Trial Investigators et al (2019) Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Ann Intern Med 170:423\u2013426. https:\/\/doi.org\/10.7326\/M18-1569","journal-title":"Ann Intern Med"},{"key":"2994_CR16","doi-asserted-by":"publisher","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS (2025) Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism 164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113","journal-title":"Metabolism"},{"key":"2994_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40842-025-00251-7","volume":"11","author":"D Tuccinardi","year":"2025","unstructured":"Tuccinardi D, Zilich R, Ponzani P, AMD Annals study group et al (2025) Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis. Cardiovasc Diabetol Endocrinol Rep 11:38. https:\/\/doi.org\/10.1186\/s40842-025-00251-7","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"2994_CR18","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.amjmed.2023.04.019","volume":"137","author":"SJ Greene","year":"2024","unstructured":"Greene SJ, Butler J, Kosiborod MN (2024) Chap. 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure. Am J Med 137:S25\u2013S34. https:\/\/doi.org\/10.1016\/j.amjmed.2023.04.019","journal-title":"Am J Med"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262\u2013276. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"2994_CR20","doi-asserted-by":"publisher","first-page":"e094853","DOI":"10.1136\/bmjopen-2024-094853","volume":"15","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP, Taveira-Gomes T, Lopes R, Seabra-Carvalho D, Bernardo F, Gavina C (2025) Prognostic impact of heart failure, chronic kidney disease and atherosclerotic disease alone or combined in an elderly population: a retrospective cohort study based on electronic health record data. Br Med J Open 15:e094853. https:\/\/doi.org\/10.1136\/bmjopen-2024-094853","journal-title":"Br Med J Open"},{"key":"2994_CR21","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","volume":"71","author":"DE Forman","year":"2018","unstructured":"Forman DE, Maurer MS, Boyd C et al (2018) Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol 71:2149\u20132161. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.022","journal-title":"J Am Coll Cardiol"},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(20)30230-8","volume":"8","author":"MN Munshi","year":"2020","unstructured":"Munshi MN, Meneilly GS, Rodr\u00edgrez-Manas L et al (2020) Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol 8:855\u2013867. https:\/\/doi.org\/10.1016\/S2213-8587(20)30230-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"101419","DOI":"10.1016\/j.diabet.2023.101419","volume":"49","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ, Bonnet F (2023) Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit\/risk balance? Diabetes Metab 49:101419. https:\/\/doi.org\/10.1016\/j.diabet.2023.101419","journal-title":"Diabetes Metab"},{"key":"2994_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1507\/endocrj.EJ21-0616","volume":"69","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shao X, Liu Z (2022) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocr J 69:669\u2013679. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0616","journal-title":"Endocr J"},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","volume":"53","author":"CJ Lavie","year":"2009","unstructured":"Lavie CJ, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53:1925\u20131932. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.068","journal-title":"J Am Coll Cardiol"},{"key":"2994_CR26","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"2994_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jama.2025.20835","volume":"335","author":"N Staplin","year":"2026","unstructured":"Staplin N, Roddick AJ, Neuen BN et al (2026) Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis. JAMA 335:220\u2013232. https:\/\/doi.org\/10.1001\/jama.2025.20835","journal-title":"JAMA"},{"key":"2994_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11255-022-03392-1","volume":"55","author":"ND Karakousis","year":"2023","unstructured":"Karakousis ND, Biliou S, Pyrgioti EE, Georgakopoulos PN, Liakopoulos V, Papanas N (2023) Frailty, sarcopenia and diabetic kidney disease: where do we stand? Int Urol Nephrol 55:1173\u20131181. https:\/\/doi.org\/10.1007\/s11255-022-03392-1","journal-title":"Int Urol Nephrol"},{"key":"2994_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13098-022-00972-0","volume":"15","author":"SC Weng","year":"2023","unstructured":"Weng SC, Lin CF, Hsu CY, Lin SY (2023) Effect of frailty, physical performance, and chronic kidney disease on mortality in older patients with diabetes: a retrospective longitudinal cohort study. Diabetol Metab Syndr 15:7. https:\/\/doi.org\/10.1186\/s13098-022-00972-0","journal-title":"Diabetol Metab Syndr"},{"key":"2994_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ajcn\/82.5.923","volume":"82","author":"DT Villareal","year":"2005","unstructured":"Villareal DT, Apovian CM, Kushner RF, Klein S, The Obesity Society, American Society for Nutrition, NAASO (2005) Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, the Obesity Society. Am J Clin Nutr 82:923\u2013934. https:\/\/doi.org\/10.1093\/ajcn\/82.5.923","journal-title":"Am J Clin Nutr"},{"key":"2994_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40520-025-03197-z","volume":"37","author":"O Erdo\u011fan","year":"2025","unstructured":"Erdo\u011fan O, Erdo\u011fan T, \u00d6n\u00fcr NH, \u00d6zk\u00f6k S, Karan MA, Bahat G (2025) Beyond BMI: central obesity measures and cardiovascular risk in late life. Aging Clin Exp Res 37:287. https:\/\/doi.org\/10.1007\/s40520-025-03197-z","journal-title":"Aging Clin Exp Res"},{"key":"2994_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1046\/j.1532-5415.2001.49189.x","volume":"49","author":"DC Grabowski","year":"2001","unstructured":"Grabowski DC, Ellis JE (2001) High body mass index does not predict mortality in older people: analysis of the longitudinal study of aging. J Am Geriatr Soc 49:968\u2013979. https:\/\/doi.org\/10.1046\/j.1532-5415.2001.49189.x","journal-title":"J Am Geriatr Soc"},{"key":"2994_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcard.2011.01.076","volume":"155","author":"TE Dorner","year":"2012","unstructured":"Dorner TE, Rieder A (2012) Obesity paradox in elderly patients with cardiovascular diseases. Int J Cardiol 155:56\u201365. https:\/\/doi.org\/10.1016\/j.ijcard.2011.01.076","journal-title":"Int J Cardiol"},{"key":"2994_CR34","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073\u20132081. https:\/\/doi.org\/10.1016\/S0140-6736(10)60674-5","journal-title":"Lancet"},{"key":"2994_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","volume":"20","author":"T Ninomiya","year":"2009","unstructured":"Ninomiya T, Perkovic V, de Galan BE, ADVANCE Collaborative Group et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813\u20131821. https:\/\/doi.org\/10.1681\/ASN.2008121270","journal-title":"J Am Soc Nephrol"},{"key":"2994_CR36","doi-asserted-by":"publisher","unstructured":"Hou Q, Zhao Y, Wu Y (2025) Medication adherence trajectories and clinical outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Glob Health 15(04145). https:\/\/doi.org\/10.7189\/jogh.15.04145","DOI":"10.7189\/jogh.15.04145"},{"key":"2994_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40266-025-01249-7","volume":"42","author":"EAR Stanly","year":"2025","unstructured":"Stanly EAR, Vilakkathala R, George J (2025) Medication Non-adherence in Older Adults: Underlying Factors, Potential Interventions and Outcomes. Drugs Aging 42:991\u20131000. https:\/\/doi.org\/10.1007\/s40266-025-01249-7","journal-title":"Drugs Aging"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02994-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:03:11Z","timestamp":1793412191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02994-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02994-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Authors have nothing to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}